GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » Gross-Profit-to-Asset %

Andros Pharmaceuticals Co (ROCO:6917) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Andros Pharmaceuticals Co's annualized Gross Profit for the quarter that ended in Dec. 2024 was NT$-0.01 Mil. Andros Pharmaceuticals Co's average Total Assets over the quarter that ended in Dec. 2024 was NT$460.86 Mil. Therefore, Andros Pharmaceuticals Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.

Andros Pharmaceuticals Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Andros Pharmaceuticals Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co Gross-Profit-to-Asset % Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial 1.40 6.28 0.43 0.07 -

Andros Pharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.09 0.08 0.01 -

Competitive Comparison of Andros Pharmaceuticals Co's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Andros Pharmaceuticals Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Andros Pharmaceuticals Co's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's Gross-Profit-to-Asset % falls into.


;
;

Andros Pharmaceuticals Co Gross-Profit-to-Asset % Calculation

Andros Pharmaceuticals Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=0.01/( (529.146+441.48)/ 2 )
=0.01/485.313
=0.00 %

Andros Pharmaceuticals Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=-0.014/( (480.247+441.48)/ 2 )
=-0.014/460.8635
=-0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Andros Pharmaceuticals Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Andros Pharmaceuticals Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » Gross-Profit-to-Asset %
Comparable Companies
ROCO:3205 ROCO:6999 ROCO:6652 ROCO:6662 ROCO:6549 ROCO:6827 ROCO:4170 ROCO:6876 ROCO:6709 ROCO:3118 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Website
http://www.androspharma.com
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co Headlines

No Headlines